Cargando…

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis

Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities. We investigated the application of chitosan nanoparticles as a DDS for the treatment of cutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riezk, Alaa, Van Bocxlaer, Katrien, Yardley, Vanessa, Murdan, Sudaxshina, Croft, Simon L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504813/ https://www.ncbi.nlm.nih.gov/pubmed/32887341 http://dx.doi.org/10.3390/molecules25174002

Ejemplares similares

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2017)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana In Vitro
por: Riezk, Alaa, et al.
Publicado: (2020)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2023)

Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021)

Development of an in vitro media perfusion model of Leishmania major macrophage infection
por: O’Keeffe, Alec, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2019)

Amphotericin B Polymer Nanoparticles Show Efficacy against Candida Species Biofilms
por: Alakkad, Abdulghani, et al.
Publicado: (2022)

Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021)

Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of Cutaneous leishmaniasis
por: Anjum, Adnan, et al.
Publicado: (2023)

Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs
por: O’Keeffe, Alec, et al.
Publicado: (2020)

Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2014)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
por: Sousa-Batista, Ariane J., et al.
Publicado: (2019)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
por: Guery, Romain, et al.
Publicado: (2017)

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2019)

Improvement of the Solubility Amphotericin B Using Olive Oil Nanoemulsion Coated with Chitosan for More Effective Treatment of Zoonotic Cutaneous Leishmaniasis
por: Taghizadeh, Elnaz, et al.
Publicado: (2021)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
por: Aronson, Naomi E, et al.
Publicado: (2018)

An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis
por: Ribeiro, Tatiana G, et al.
Publicado: (2014)

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis
por: Parvez, Shabi, et al.
Publicado: (2020)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis
por: Shirzadi, Mohammad Reza
Publicado: (2019)

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
por: Kosaka, Atsushi, et al.
Publicado: (2020)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis
por: Loiseau, Philippe M., et al.
Publicado: (2020)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Ocular Leishmaniasis Treated by Intralesional Amphotericin B
por: Nikandish, Malihe, et al.
Publicado: (2016)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis
por: Chivinski, Jeffrey, et al.
Publicado: (2023)

Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview
por: Palma, Ernesto, et al.
Publicado: (2018)

Amphotericin B Loaded Polymeric Nanoparticles for Treatment of Leishmania Infections
por: Saqib, Mudassara, et al.
Publicado: (2020)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h4q7e257n54i2j9t5c03pfbqnp